XML 61 R43.htm IDEA: XBRL DOCUMENT
v3.20.4

Equity (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Summary of Stock Option Activity | A summary of the status of the options granted by Teva as of December 31, 2020, 2019 and 2018, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof).
|  | Year ended December 31, |
|  | 2020 |  |  | 2019 |  |  | 2018 |
|  | Number (in thousands) |  |  | Weighted average exercise price |  |  | Number (in thousands) |  |  | Weighted average exercise price |  |  | Number (in thousands) |  |  | Weighted average exercise price |
Balance outstanding at beginning of year |  |  | 40,064 |  |  | $ | 37.90 |  |  |  | 48,393 |  |  | $ | 38.62 |  |  |  | 43,121 |  |  | $ | 44.32 |
Changes during the year: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Granted |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 12,401 |  |  |  | 19.12 |
Exercised |  |  | — |  |  |  | — |  |  |  | (11 | ) |  |  | 16.99 |  |  |  | (84 | ) |  |  | 17.01 |
Forfeited |  |  | (3,610 | ) |  |  | 40.24 |  |  |  | (8,318 | ) |  |  | 42.12 |  |  |  | (7,040 | ) |  |  | 39.38 |
Expired |  |  | (1,220 | ) |  |  | 49.35 |  |  |  | — |  |  |  | — |  |  |  | (5 | ) |  |  | 50.65 |
Balance outstanding at end of year |  |  | 35,234 |  |  |  | 37.27 |  |  |  | 40,064 |  |  |  | 37.90 |  |  |  | 48,393 |  |  |  | 38.62 |
Balance exercisable at end of year |  |  | 28,556 |  |  |  | 40.56 |  |  |  | 26,601 |  |  |  | 43.41 |  |  |  | 24,086 |  |  |  | 46.89 |
Summary of Weighted Average Fair Value of Options Granted | The weighted average fair value of options granted during these years was generally estimated by using the Black-Scholes option-pricing model as follows:
|  | Year ended December 31, |
|  | 2020 |  |  | 2019 |  |  | 2018 |
Weighted average fair value |  |  | — |  |  |  | — |  |  | $ | 7.4 |
Summary of Fair Value of Options Estimated on Date of Grant Based on Weighted Average Assumptions | The fair value of these options was estimated on the date of grant, based on the following weighted average assumptions:
|  | Year ended December 31, |
|  | 2020 |  |  | 2019 |  |  | 2018 |
Expected volatility |  |  | — |  |  |  | — |  |  |  | 40 | %
Risk-free interest rate |  |  | — |  |  |  | — |  |  |  | 2.6 | %
Expected term |  |  | — |  |  |  | — |  |  |  | 5 years |
Schedule of Ordinary Shares Issued Upon Outstanding Options | The following tables summarize information as of December 31, 2020 regarding the number of ordinary shares issuable upon (1) outstanding options and (2) vested options:
(1) Number of ordinary shares issuable upon exercise of outstanding options |
Range of exercise prices |  | Balance at end of period (in thousands) |  |  | Weighted average exercise price |  |  | Weighted average remaining life |
|  | Number of shares |  |  | $ |  |  | Years |  |
Lower than $15.01 |  |  | 592 |  |  |  | 11.40 |  |  |  | 6.84 |  |
$15.01 - $25.00 |  |  | 10,087 |  |  |  | 18.93 |  |  |  | 7.12 |  |
$25.01 - $35.00 |  |  | 7,221 |  |  |  | 34.61 |  |  |  | 6.16 |  |
$35.01 - $45.00 |  |  | 5,216 |  |  |  | 40.66 |  |  |  | 1.46 |  |
$45.01 - $55.00 |  |  | 7,895 |  |  |  | 51.06 |  |  |  | 4.10 |  |
$55.01 - $65.00 |  |  | 4,223 |  |  |  | 59.26 |  |  |  | 4.30 |  |
Total |  |  | 35,234 |  |  |  | 37.27 |  |  |  | 5.07 |  |
Schedule of Ordinary Shares Issued Upon Vested Options |
(2) Number of ordinary shares issuable upon exercise of vested options |
Range of exercise prices |  | Balance at end of period (in thousands) |  |  | Weighted average exercise price |  |  | Weighted average remaining life |
|  | Number of shares |  |  | $ |  |  | Years |  |
Lower than $15.01 |  |  | 394 |  |  |  | 11.40 |  |  |  | 6.84 |  |
$15.01 - $25.00 |  |  | 5,431 |  |  |  | 18.81 |  |  |  | 7.09 |  |
$25.01 - $35.00 |  |  | 5,423 |  |  |  | 34.61 |  |  |  | 6.16 |  |
$35.01 - $45.00 |  |  | 5,216 |  |  |  | 40.66 |  |  |  | 1.46 |  |
$45.01 - $55.00 |  |  | 7,895 |  |  |  | 51.06 |  |  |  | 4.10 |  |
$55.01 - $65.00 |  |  | 4,197 |  |  |  | 59.28 |  |  |  | 4.30 |  |
Total |  |  | 28,556 |  |  |  | 40.56 |  |  |  | 4.65 |  |
Schedule of the Number of RSUs Issued and Outstanding | The following table summarizes information about the number of RSUs and PSUs granted and outstanding:
|  | Year ended December 31, |
|  | 2020 |  |  | 2019 |  |  | 2018 |
|  | Number (in thousands) |  |  | Weighted average grant date fair value |  |  | Number (in thousands) |  |  | Weighted average grant date fair value |  |  | Number (in thousands) |  |  | Weighted average grant date fair value |
Balance outstanding at beginning of year |  |  | 15,977 |  |  | $ | 16.49 |  |  |  | 10,403 |  |  | $ | 20.93 |  |  |  | 7,468 |  |  | $ | 27.95 |
Granted |  |  | 10,848 |  |  |  | 11.42 |  |  |  | 9,303 |  |  |  | 15.36 |  |  |  | 5,900 |  |  |  | 18.80 |
Vested |  |  | (4,324 | ) |  |  | 19.49 |  |  |  | (2,435 | ) |  |  | 30.24 |  |  |  | (1,638 | ) |  |  | 37.30 |
Forfeited |  |  | (1,781 | ) |  |  | 18.18 |  |  |  | (1,294 | ) |  |  | 18.74 |  |  |  | (1,327 | ) |  |  | 32.50 |
Balance outstanding at end of year |  |  | 20,720 |  |  |  | 13.81 |  |  |  | 15,977 |  |  |  | 16.49 |  |  |  | 10,403 |  |  |  | 20.93 |
Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value | The Company expenses compensation costs are based on the grant-date fair value. For the years ended December 31, 2020, 2019 and 2018, the Company recorded stock-based compensation costs as follows:
|  | Year ended December 31, |
|  | 2020 |  |  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
Employee stock options |  | $ | 30 |  |  | $ | 46 |  |  | $ | 74 |
RSUs and PSUs |  |  | 99 |  |  |  | 73 |  |  |  | 81 |
Total stock-based compensation expense |  |  | 129 |  |  |  | 119 |  |  |  | 155 |
Tax effect on stock-based compensation expense |  |  | 14 |  |  |  | 14 |  |  |  | 18 |
Net effect |  | $ | 115 |  |  | $ | 105 |  |  | $ | 137 |
Accumulated Other Comprehensive Income/(Loss) (Net of Tax) | The components of accumulated other comprehensive loss attributable to Teva are presented in the table below:
|  | Net Unrealized Gains/(Losses) |  |  | Benefit Plans |  |  |  |
|  | Foreign currency translation adjustments |  |  | Available- for-sale securities |  |  | Derivative financial instruments |  |  | Actuarial gains/(losses) and prior service (costs)/credits |  |  | Total |
|  | (U.S. $ in millions) |
Balance as of January 1, 2018 |  | $ | (1,139 | ) |  | $ | (4 | ) |  | $ | (619 | ) |  | $ | (91 | ) |  | $ | (1,853 | )
Cumulative effect of new accounting standard** |  |  | — |  |  |  | 5 |  |  |  | — |  |  |  | — |  |  |  | 5 |
Other comprehensive income/(loss) before reclassifications |  |  | (729 | ) |  |  | (1 | ) |  |  | 87 |  |  |  | 4 |  |  |  | (639 | )
Amounts reclassified to the statements of income |  |  | — |  |  |  | 1 |  |  |  | 28 |  |  |  | 13 |  |  |  | 42 |
Net other comprehensive income/(loss) before tax |  |  | (729 | ) |  |  | — |  |  |  | 115 |  |  |  | 17 |  |  |  | (597 | )
Corresponding income tax |  |  | (10 | ) |  |  | — |  |  |  | — |  |  |  | (4 | ) |  |  | (14 | )
Net other comprehensive income/(loss) after tax* |  |  | (739 | ) |  |  | — |  |  |  | 115 |  |  |  | 13 |  |  |  | (611 | )
Balance as of December 31, 2018 |  |  | (1,878 | ) |  |  | 1 |  |  |  | (504 | ) |  |  | (78 | ) |  |  | (2,459 | )
Other comprehensive income/(loss) before reclassifications |  |  | 100 |  |  |  | (1 | ) |  |  | 54 |  |  |  | (11 | ) |  |  | 142 |
Amounts reclassified to the statements of income |  |  | — |  |  |  | — |  |  |  | 30 |  |  |  | (10 | ) |  |  | 20 |
Net other comprehensive income/(loss) before tax |  |  | 100 |  |  |  | (1 | ) |  |  | 84 |  |  |  | (21 | ) |  |  | 162 |
Corresponding income tax |  |  | (16 | ) |  |  | — |  |  |  | — |  |  |  | 1 |  |  |  | (15 | )
Net other comprehensive income/(loss) after tax* |  |  | 84 |  |  |  | (1 | ) |  |  | 84 |  |  |  | (20 | ) |  |  | 147 |
Balance as of December 31, 2019 |  |  | (1,794 | ) |  |  | — |  |  |  | (420 | ) |  |  | (98 | ) |  |  | (2,312 | )
Other comprehensive income/(loss) before reclassifications |  |  | (190 | ) |  |  | — |  |  |  | 22 |  |  |  | (7 | ) |  |  | (175 | )
Amounts reclassified to the statements of income |  |  | — |  |  |  | — |  |  |  | 35 |  |  |  | (12 | ) |  |  | 23 |
Net other comprehensive income/(loss) before tax |  |  | (190 | ) |  |  | — |  |  |  | 57 |  |  |  | (19 | ) |  |  | (152 | )
Corresponding income tax |  |  | 65 |  |  |  | — |  |  |  | — |  |  |  | 1 |  |  |  | 66 |
Net other comprehensive income/(loss) after tax* |  |  | (125 | ) |  |  | — |  |  |  | 57 |  |  |  | (18 | ) |  |  | (86 | )
Balance as of December 31, 2020 |  | $ | (1,919 | ) |  |  | — |  |  | $ | (363 | ) |  | $ | (117 | ) |  | $ | (2,399 | )
* | Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $56 million gain in 2020 , $14 million gain in 2019 and $26 million gain in 2018.
** | Following the adoption of ASU 2016-01, the Company recorded a $5 million opening balance reclassification from accumulated other comprehensive income to retained earnings.

X
- Definition Tabular disclosure of share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration